.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP58_DaclatasvirAsunaprevirAn.DaclatasvirAsunaprevirAn .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP58_DaclatasvirAsunaprevirAn.DaclatasvirAsunaprevirAn| name: | DaclatasvirAsunaprevirAndBeclabuvir | |
| ATC code: | J05AP58 | route: | oral |
| compartments: | 1 | |
| dosage: | 30 | mg |
| volume of distribution: | 50 | L |
| clearance: | 15 | L/h |
| other parameters in model implementation | ||
The fixed-dose combination of daclatasvir, asunaprevir and beclabuvir is an oral antiviral medication that was developed for the treatment of chronic hepatitis C virus (HCV) infection in adults. Daclatasvir is an NS5A inhibitor, asunaprevir is an NS3 protease inhibitor, and beclabuvir is an NS5B polymerase inhibitor. The combination was developed for interferon-free treatment of HCV but has not received FDA approval and its global development was discontinued.
Pharmacokinetic parameters based on healthy adult volunteers after administration of the fixed-dose combination tablet under fasting conditions.
Osawa, M, et al., & Garimella, T (2019). Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. Clinical pharmacology in drug development 8(6) 802–817. DOI:10.1002/cpdd.649 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30629858